Monte Rosa Therapeutics (GLUE)
(Real Time Quote from BATS)
$12.59 USD
+0.27 (2.19%)
Updated Oct 28, 2025 12:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLUE 12.59 +0.27(2.19%)
Will GLUE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GLUE
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
Other News for GLUE
GLUE makes New 52 Week Closing High on October 27
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study
New 52 Week Closing High appears for GLUE after 7.32% move
Is GLUE gaining bullish strength? Pocket Pivot shows up after rallying 11.02%